Association between brain-derived neurotrophic factor V66M and treatment responses to escitalopram in patients with major depressive disorder

Hun Soo Chang, Hwa Young Lee, Byung-Joo Ham, Yong Chon Park, Sang Woo Hahn, Yoo Jung Jeong, Bohye Kim, Min-Soo Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: Brain-derived neurotrophic factor (BDNF) is a candidate molecule for influencing the clinical response to antidepressant treatment. Among polymorphisms on the BDNF gene, V66M (rs6265) has been reported to be associated with response to antidepressant treatment. The aims of this study were to determine the relationship between the V66M polymorphism and the response to escitalopram in patients with major depressive disorder (MDD). Methods: One hundred and fifteen Korean patients were examined using the Structured Clinical Interview for DSM-IV Axis I disorders, and took escitalopram at a daily dose of 5-40mg. Clinical symptoms were evaluated using the 21-item Hamilton Depression Rating (HAM-D) scale during 12 weeks of treatment. The genotypes were determined using NlaIII digestion. Results: The proportions of M allele carriers were higher in responders than those in non-responders at 1-8 weeks (P=0.00001-P=0.025). The percentile decrease of HAM-D scores was larger in M allele carriers than those in patients possessing VV genotype at 1-8 weeks (P=0.0002-0.002). The proportion of M allele carriers was higher in remitters than in non-remitters at 2-8 weeks (P=0.003-P=0.038). The comparison between VM heterozygotes and homozygotes (VV or MM) showed similar results. Discussion: These results suggest that BDNF V66M affects the therapeutic action of escitalopram in MDD and that this polymorphism may be a genetic marker for therapeutic response to escitalopram treatment in patients with MDD.

Original languageEnglish
Pages (from-to)241-249
Number of pages9
JournalAsia-Pacific Psychiatry
Volume4
Issue number4
DOIs
Publication statusPublished - 2012 Dec 1

Fingerprint

Citalopram
Brain-Derived Neurotrophic Factor
Major Depressive Disorder
Alleles
Antidepressive Agents
Therapeutics
Genotype
Depression
Homozygote
Heterozygote
Genetic Markers
Diagnostic and Statistical Manual of Mental Disorders
Digestion
Interviews
Genes

Keywords

  • Brain-derived neurotrophic factor
  • Escitalopram
  • Major depressive disorder
  • Single nucleotide polymorphism
  • Treatment response

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Association between brain-derived neurotrophic factor V66M and treatment responses to escitalopram in patients with major depressive disorder. / Chang, Hun Soo; Lee, Hwa Young; Ham, Byung-Joo; Park, Yong Chon; Hahn, Sang Woo; Jeong, Yoo Jung; Kim, Bohye; Lee, Min-Soo.

In: Asia-Pacific Psychiatry, Vol. 4, No. 4, 01.12.2012, p. 241-249.

Research output: Contribution to journalArticle

Chang, Hun Soo ; Lee, Hwa Young ; Ham, Byung-Joo ; Park, Yong Chon ; Hahn, Sang Woo ; Jeong, Yoo Jung ; Kim, Bohye ; Lee, Min-Soo. / Association between brain-derived neurotrophic factor V66M and treatment responses to escitalopram in patients with major depressive disorder. In: Asia-Pacific Psychiatry. 2012 ; Vol. 4, No. 4. pp. 241-249.
@article{5e90448444b0471bad260089aada466c,
title = "Association between brain-derived neurotrophic factor V66M and treatment responses to escitalopram in patients with major depressive disorder",
abstract = "Introduction: Brain-derived neurotrophic factor (BDNF) is a candidate molecule for influencing the clinical response to antidepressant treatment. Among polymorphisms on the BDNF gene, V66M (rs6265) has been reported to be associated with response to antidepressant treatment. The aims of this study were to determine the relationship between the V66M polymorphism and the response to escitalopram in patients with major depressive disorder (MDD). Methods: One hundred and fifteen Korean patients were examined using the Structured Clinical Interview for DSM-IV Axis I disorders, and took escitalopram at a daily dose of 5-40mg. Clinical symptoms were evaluated using the 21-item Hamilton Depression Rating (HAM-D) scale during 12 weeks of treatment. The genotypes were determined using NlaIII digestion. Results: The proportions of M allele carriers were higher in responders than those in non-responders at 1-8 weeks (P=0.00001-P=0.025). The percentile decrease of HAM-D scores was larger in M allele carriers than those in patients possessing VV genotype at 1-8 weeks (P=0.0002-0.002). The proportion of M allele carriers was higher in remitters than in non-remitters at 2-8 weeks (P=0.003-P=0.038). The comparison between VM heterozygotes and homozygotes (VV or MM) showed similar results. Discussion: These results suggest that BDNF V66M affects the therapeutic action of escitalopram in MDD and that this polymorphism may be a genetic marker for therapeutic response to escitalopram treatment in patients with MDD.",
keywords = "Brain-derived neurotrophic factor, Escitalopram, Major depressive disorder, Single nucleotide polymorphism, Treatment response",
author = "Chang, {Hun Soo} and Lee, {Hwa Young} and Byung-Joo Ham and Park, {Yong Chon} and Hahn, {Sang Woo} and Jeong, {Yoo Jung} and Bohye Kim and Min-Soo Lee",
year = "2012",
month = "12",
day = "1",
doi = "10.1111/j.1758-5872.2012.00219.x",
language = "English",
volume = "4",
pages = "241--249",
journal = "Asia-Pacific Psychiatry",
issn = "1758-5864",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Association between brain-derived neurotrophic factor V66M and treatment responses to escitalopram in patients with major depressive disorder

AU - Chang, Hun Soo

AU - Lee, Hwa Young

AU - Ham, Byung-Joo

AU - Park, Yong Chon

AU - Hahn, Sang Woo

AU - Jeong, Yoo Jung

AU - Kim, Bohye

AU - Lee, Min-Soo

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Introduction: Brain-derived neurotrophic factor (BDNF) is a candidate molecule for influencing the clinical response to antidepressant treatment. Among polymorphisms on the BDNF gene, V66M (rs6265) has been reported to be associated with response to antidepressant treatment. The aims of this study were to determine the relationship between the V66M polymorphism and the response to escitalopram in patients with major depressive disorder (MDD). Methods: One hundred and fifteen Korean patients were examined using the Structured Clinical Interview for DSM-IV Axis I disorders, and took escitalopram at a daily dose of 5-40mg. Clinical symptoms were evaluated using the 21-item Hamilton Depression Rating (HAM-D) scale during 12 weeks of treatment. The genotypes were determined using NlaIII digestion. Results: The proportions of M allele carriers were higher in responders than those in non-responders at 1-8 weeks (P=0.00001-P=0.025). The percentile decrease of HAM-D scores was larger in M allele carriers than those in patients possessing VV genotype at 1-8 weeks (P=0.0002-0.002). The proportion of M allele carriers was higher in remitters than in non-remitters at 2-8 weeks (P=0.003-P=0.038). The comparison between VM heterozygotes and homozygotes (VV or MM) showed similar results. Discussion: These results suggest that BDNF V66M affects the therapeutic action of escitalopram in MDD and that this polymorphism may be a genetic marker for therapeutic response to escitalopram treatment in patients with MDD.

AB - Introduction: Brain-derived neurotrophic factor (BDNF) is a candidate molecule for influencing the clinical response to antidepressant treatment. Among polymorphisms on the BDNF gene, V66M (rs6265) has been reported to be associated with response to antidepressant treatment. The aims of this study were to determine the relationship between the V66M polymorphism and the response to escitalopram in patients with major depressive disorder (MDD). Methods: One hundred and fifteen Korean patients were examined using the Structured Clinical Interview for DSM-IV Axis I disorders, and took escitalopram at a daily dose of 5-40mg. Clinical symptoms were evaluated using the 21-item Hamilton Depression Rating (HAM-D) scale during 12 weeks of treatment. The genotypes were determined using NlaIII digestion. Results: The proportions of M allele carriers were higher in responders than those in non-responders at 1-8 weeks (P=0.00001-P=0.025). The percentile decrease of HAM-D scores was larger in M allele carriers than those in patients possessing VV genotype at 1-8 weeks (P=0.0002-0.002). The proportion of M allele carriers was higher in remitters than in non-remitters at 2-8 weeks (P=0.003-P=0.038). The comparison between VM heterozygotes and homozygotes (VV or MM) showed similar results. Discussion: These results suggest that BDNF V66M affects the therapeutic action of escitalopram in MDD and that this polymorphism may be a genetic marker for therapeutic response to escitalopram treatment in patients with MDD.

KW - Brain-derived neurotrophic factor

KW - Escitalopram

KW - Major depressive disorder

KW - Single nucleotide polymorphism

KW - Treatment response

UR - http://www.scopus.com/inward/record.url?scp=84870820845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870820845&partnerID=8YFLogxK

U2 - 10.1111/j.1758-5872.2012.00219.x

DO - 10.1111/j.1758-5872.2012.00219.x

M3 - Article

VL - 4

SP - 241

EP - 249

JO - Asia-Pacific Psychiatry

JF - Asia-Pacific Psychiatry

SN - 1758-5864

IS - 4

ER -